Organization of chemotherapeutic preparations in advance: Do we save or waste money?

J Oncol Pharm Pract. 2021 Oct;27(7):1699-1703. doi: 10.1177/1078155220967981. Epub 2020 Oct 27.

Abstract

Objective: The development of oncology day-hospital activities contributes to increase quality of life of patients and consequently have changed their perception about waiting. The extemporaneous preparation of antineoplastic has become difficult to achieve given the increasing activity, and hospital pharmacists have taken up the challenge by the implementation of the antineoplastic preparation in anticipation. Because anticipation can lead to an important number of preparations to be discarded, we also develop a recycled process for other patients to limit these waste extra costs. We aim to demonstrate the positive balance of anticipated preparation in this 4-year study report.Data sources: This prospective study was conducted in a major European oncology day-hospital from January, 2012 to December, 2015. The data were extracted from our software WinSimbad™ and updated as needed. The number and cost-associated of preparation ungiven chemotherapy doses (recycled or discarded) were compared to the global drug budget of our hospital in order to not exceed 2%.Data summary: 303,100 antineoplastic have been prepared. Approximately 35% of them were anticipated with an average of 5,431±984 that were finally ungiven. Two-third was recycled and the cost of the ungiven preparations finally discarded represents 1.7±0.15% of the global drug budget.

Conclusions: This study assesses the drug wastage and its associated cost of this concept through a prospective study and discusses the cost of ungiven antineoplastic preparations. With prior consideration of the need to define the acceptable rate of discarded ungiven preparation, the hospitals with an high oncology day-hospital activity should implement this approach.

Keywords: Antineoplastic; anticipation; chemotherapy; cost efficiency; preparation.

MeSH terms

  • Antineoplastic Agents*
  • Humans
  • Medical Oncology
  • Pharmacists
  • Prospective Studies
  • Quality of Life*

Substances

  • Antineoplastic Agents